Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
See Latest ArticlesExperience of Mycophenolate Mofetil in 10 Patients With Autoimmune-Related Interstitial Lung Disease Demonstrates Promising Effects
The American Journal of the Medical Sciences, 06/11/09
Saketkoo LA et al. - MMF is safe, well tolerated, and allows reduction or discontinuation of prednisone without worsening of symptoms or objective progression of disease. MMF is less toxic and its targeted antifibrotic properties make it a potentially more effective agent than CYC that may supplant it as a first-line agent or provide sensible post-CYC maintenance or synergistic strategy in the treatment of CTD-ILD.
Today in Restrictive Lung Dz...keeping you current
Receive free subspecialty "5-minute updates" via email
Lung involvement in patients with primary Sjögrens syndrome: What are the predictors?
Rheumatology International, 10/26/09
Pulmonary Nodulosis and Aseptic Granulomatous Lung Disease Occurring in Patients with Rheumatoid Arthritis Receiving Tumor Necrosis Factor-alpha-Blocking Agent: A Case Series
Journal of Rheumatology, 10/07/09
Effects of pulmonary rehabilitation in patients with restrictive lung diseases
Chest, 10/29/09
Sponsor
Article Search
Sponsor